Arcevo LSA stent graft for repairing aortic arch dissections and aneurysms

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional device study implants the Arcevo™ LSA Hybrid Stent Graft System during open surgical repair for patients with acute, subacute, or chronic aortic dissection or aneurysm involving the aortic arch and descending thoracic aorta. Eligible adults (18–80 years) must have preoperative CTA within 90 days and undergo surgery within 90 days of consent, with specific anatomic requirements such as aortic diameter ≥21 mm at the planned LSA anastomosis. Outcomes will focus on procedural safety and technical effectiveness, with follow-up imaging to document sealing and complication rates. The trial is conducted at several academic medical centers in the United States.

Why it matters

Who can join: the full rules

General Inclusion Criteria

1. ≥18 years of age or ≤80 years of age (male or female) at time of surgery
2. Patient has one of the following indications for open surgery based on computed tomography angiography (CTA) completed within 90 days of informed consent:

   * Acute, subacute, or chronic dissection that involves the aortic arch and the descending thoracic aorta, with or without involvement of the ascending aorta
   * Aneurysm that involves the aortic arch and the descending thoracic aorta, with or without involvement of the ascending aorta
3. Patient, or patient's legally authorized representative (LAR; in the secondary arm only), provides written informed consent prior to any study procedures
4. Patient's surgery occurs within 90 days of informed consent

   Anatomical Inclusion Criteria
5. Aortic diameter at the intended Arcevo™ LSA anastomosis site is ≥ 21 mm
6. For Aneurysm with distal sealing (i.e., single stage procedure), aortic diameter at the intended distal sealing zone is between 20-36 mm
7. For Dissection with distal sealing, aortic diameter at the intended distal sealing zone is between 22-40 mm
8. LSA branch does not require additional stenting further into the LSA (beyond the Arcevo™ LSA)
9. The intended LSA sealing zone has a diameter between 8.5 mm and 14.0 mm with a length of at least 10 mm
10. Absence of dissection, aneurysm, or stenosis in the intended LSA sealing zone
11. The intended LSA branch position does not interrupt flow to any branch vessel (e.g., left vertebral artery)
12. Patient does not have computed tomography (CT) evidence of extreme arch or LSA angulation precluding safe passage of the Arcevo™ LSA and delivery system
13. LSA take-off angle between 15° and 90°
14. For patients requiring planned extension, there is a ≥ 2 cm distal seal zone for the TEVAR device without a severely angulated descending aorta
15. For patients requiring planned extension, patient has suitable iliac artery anatomy for safe passage of the TEVAR delivery system

General Exclusion Criteria

1. Patient is pregnant, or planning to become pregnant during the course of the study; individuals of child-bearing potential must agree to use acceptable methods of contraception during the study
2. Patient has another medical condition (aside from the arch disease) that, in the opinion of the investigator, reduces the patient's life expectancy to \< 2 years
3. Patient has an existing aortic stent graft device in the descending aorta that would interact with Arcevo™ LSA
4. Patient has a medical, social, or psychological problem that, in the opinion of the investigator, could impede the patient's ability to return for follow-up
5. Patient is unwilling or unable to comply with the follow-up schedule
6. Patient is institutionalized due to administrative or judicial order
7. Patient is unwilling to accept blood transfusion or blood product
8. Patient is currently participating in another interventional clinical study which includes treatment with another investigational product (e.g., device, pharmaceutical or biologic)

   Medical Exclusion Criteria
9. Patient is unfit for open surgical repair involving circulatory arrest
10. Patient is in extreme hemodynamic compromise requiring cardiopulmonary resuscitation (CPR) or substantial inotropic support prior to surgery
11. Patient has an active systemic infection
12. Patient has endocarditis or active infection of the aorta
13. Patient has a freely ruptured aorta
14. Patient has a history of a bleeding disorder (e.g., hemophilia)
15. Patient has current end-stage renal disease (e.g., GFR \<30 mL/min)
16. Patient has a known allergy to Arcevo™ LSA components and TEVAR device components (if required) (nitinol, polyester, platinum-iridium, or polyethylene)
17. Patient has uncontrollable anaphylaxis to iodinated contrast or other inability to obtain CT angiograms during follow-up
18. Patient has acute coronary malperfusion
19. Patient has symptomatic visceral malperfusion

Where it's running

• University of Alabama
  Birmingham, Alabama, United States Recruiting
• University of Southern California
  Los Angeles, California, United States Recruiting
• University of Colorado Hospital
  Aurora, Colorado, United States Recruiting
• MedStar Washington Health
  Washington D.C., District of Columbia, United States Recruiting
• University of Florida-Shands
  Gainesville, Florida, United States Recruiting
• Emory University School of Medicine
  Atlanta, Georgia, United States Recruiting

Study contacts

• Study coordinator: Erin M Adams, MSPH
• Email: ARTIZEN@artivion.com
• Phone: 800-438-8285

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• GORE TBE Device in Zone 0/1 for Aortic Arch Conditions

  This study tests the GORE TAG Thoracic Branch Endoprosthesis in adults with aortic arch problems in Zone 0 or 1 to see how it performs over several years in routine care.

  Recruiting at 24 sites W.L.Gore & Associates · Scottsdale, Arizona and 23 other locations · NCT07166133

• Collecting data on custom-made stent-graft devices for aortic treatment

  This study is testing how safe and effective custom-made stent-grafts are for treating complex aortic conditions in real-world settings.

  Recruiting at 18 sites Cook Group Incorporated · Aarhus, Denmark and 17 other locations · NCT05896397

• Repairing complex aortic aneurysms with a specialized stent-graft

  This study is testing a special stent-graft to see if it safely and effectively repairs complex aortic aneurysms in patients who have them.

  Recruiting Baylor College of Medicine · Rochester, Minnesota and 2 other locations · NCT02089607

• Triple-branched stent graft system for aortic arch lesions

  This trial tests whether the triple branched covered stent graft can safely treat aortic arch lesions and achieve a high 12‑month treatment success with a low 30‑day major adverse events in adults.

  Recruiting Changhai Hospital · Shanghai, Shanghai Municipality · NCT07067840

• Endovascular treatment for aortic arch diseases using a new stent-graft system

  This study is testing a new stent-graft system to see if it can safely and effectively treat aortic arch diseases like aneurysms and ulcers in patients aged 18 to 80.

  Recruiting at 16 sites Lifetech Scientific (Shenzhen) Co., Ltd. · Beijing and 16 other locations · NCT06520774

• A study on a new stent graft system for aortic arch aneurysms

  This study is testing a new stent graft system to see if it can safely and effectively treat aortic arch aneurysms in patients.

  Recruiting at 20 sites Hangzhou Endonom Medtech Co., Ltd. · Beijing and 19 other locations · NCT06385379

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.